Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jul 11, 2026·v1

Clostridioides difficile

Clostridioides difficile infection (CDI) is a major healthcare-associated toxin-mediated diarrheal illness with significant morbidity and mortality. Diagnosis requires a multistep algorithm (GDH + toxin EIA) to distinguish infection from colonization. Fidaxomicin is the preferred first-line therapy for initial CDI due to its lower recurrence rate and microbiome-sparing effect. Vancomycin remains an alternative. For fulminant disease, high-dose vancomycin plus IV metronidazole is indicated, with early surgical consultation. Recurrence, affecting 15-30% of patients, can be mitigated with bezlotoxumab, vancomycin taper, or microbiome-based therapies (FMT, SER-109). Antimicrobial stewardship, particularly minimizing unnecessary antibiotic use, is the cornerstone of prevention.

High Evidence330 references·10,122 words·41 min read·v1
Clostridioides difficileCDIhealthcare-associated infectiondiarrheapseudomembranous colitistoxinantibiotic stewardshipfidaxomicinvancomycinbezlotoxumabfecal microbiota transplantationrecurrent CDIbinary toxinribotype 027

Quick Reference

RxDrug of choiceFidaxomicin 200 mg PO BID x10 days for initial non-severe/severe CDI. For fulminant: vancomycin 500 mg PO/NG QID + IV metronidazole 500 mg q8h.
AltAlternativesVancomycin 125 mg PO QID x10 days when fidaxomicin unavailable. For recurrence: vancomycin taper/pulse or bezlotoxumab 10 mg/kg IV single dose as adjunct.
⊘AvoidMetronidazole monotherapy for initial episode; antiperistaltic agents (opioids, loperamide); routine probiotics; avoid high-risk antibiotics (carbapenems, cephalosporins, fluoroquinolones, clindamycin) when possible.
DxTest of choiceMultistep algorithm: GDH EIA as initial screen, followed by toxin A/B EIA for confirmation. NAAT alone is insufficient; use NAAT + toxin EIA if GDH unavailable.
ScKey scoreIDSA severity criteria: severe if WBC ≥15,000 cells/µL or serum creatinine >1.5 mg/dL; fulminant if hypotension, ileus, or toxic megacolon.
→When to referSurgical consult for fulminant CDI (toxic megacolon, perforation, refractory shock). Infectious disease consult for recurrent or complicated cases, especially in immunocompromised hosts.
Fidaxomicin is first-line for initial CDI due to lower recurrence and microbiome preservation. Toxin-based diagnosis is essential to avoid overtreatment. Recurrence prevention includes bezlotoxumab, vancomycin taper, and microbiome therapies. Antimicrobial stewardship is the most effective prevention strategy.
Clostridioides difficile infection (CDI) is a toxin-mediated diarrheal illness caused by the spore-forming, anaerobic bacterium C. difficile. It is the leading cause of healthcare-associated diarrhea in US hospitals, with an incidence of 46.6 per 10,000 admissions. The clinical spectrum ranges from mild diarrhea to life-threatening pseudomembranous colitis and toxic megacolon. Diagnosis requires a multistep algorithm (GDH + toxin EIA) to distinguish true infection from colonization. Fidaxomicin is now the preferred first-line therapy for initial CDI due to its lower recurrence rate and microbiome-sparing properties. For fulminant disease, high-dose oral vancomycin plus intravenous metronidazole is recommended. Recurrence remains a major challenge, affecting 15-30% of patients; strategies include bezlotoxumab, vancomycin taper, and microbiome-based therapies such as fecal microbiota transplantation. Antimicrobial stewardship is the cornerstone of prevention, as antibiotic exposure is the dominant modifiable risk factor.

Overview and Recommendations

Key Facts

  • •Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea in US hospitals, with an incidence of 46.6 per 10,000 admissions. The causative organism is an obligate anaerobic, Gram-positive, spore-forming bacillus that produces two primary exotoxins, toxin A (TcdA) and toxin B (TcdB), and, in some strains, a binary toxin (CDT). Spores are resistant to heat, alcohol, and many disinfectants, enabling environmental persistence and transmission.
  • •Hypervirulent strains, particularly ribotype 027 (NAP1/BI), carry the binary toxin gene locus and are associated with higher 30-day attributable mortality (pooled RR 1.96) and increased rates of ICU admission, , or CDI-associated death (RR 1.88). The emergence of these strains has shifted the epidemiology of CDI, with community-associated cases now accounting for a growing proportion.
  • •Pathogenesis hinges on disruption of the gut microbiome by antibiotics, which reduces colonization resistance and allows germination of ingested spores into toxin-producing vegetative cells. The toxins inactivate small GTPases (Rho, Rac, Cdc42), leading to actin cytoskeleton disorganization, tight junction disruption, epithelial apoptosis, and neutrophilic inflammation, the clinical hallmarks of diarrhea and colitis.
  • •Stool (IL-1β), an inflammasome pathway cytokine, accurately differentiates CDI from asymptomatic carriage (AUROC 0.88) and from non-CDI diarrhea (AUROC 0.83), reflecting the degree of toxin-driven inflammation. This emerging biomarker may help address the critical gap between colonization and infection.
  • •Recurrent CDI occurs in 15-30% of patients after initial therapy, driven by persistent dysbiosis and failure to restore secondary bile acid metabolism. Risk factors include age ≥65 years, continued non-CDI antibiotic use, severe underlying illness, and prior CDI episodes.
  • •Antibiotic exposure is the dominant modifiable risk factor: each day of outpatient antibiotic therapy prior to admission increases the odds of subsequent CDI by 12.8%. Carbapenems and third-/fourth-generation cephalosporins carry the strongest association with healthcare facility-associated CDI, while clindamycin confers the highest risk for community-associated CDI (aOR 8.81 vs ).

Clinical Importance

  • •Suspect CDI in any patient with ≥3 unformed stools in 24 hours for at least 1-2 days, especially if there is a history of antibiotic use within the past 8 weeks, hospitalization, or residence in a long-term care facility.
  • •Ask about recent antibiotic exposure (type, duration, route), prior CDI episodes, PPI use, hospitalization history, and underlying conditions such as (IBD), malignancy, or immunosuppression.
  • •Examine for abdominal tenderness, distension, decreased bowel sounds (suggesting ileus), fever, tachycardia, and signs of hypovolemia or shock. In severe cases, look for rigidity or guarding suggesting perforation.
  • •Order diagnostic testing only on liquid stool (taking the shape of the container). Formed stools should be rejected. Use a multistep algorithm: first test for C. difficile antigen (GDH EIA) or use NAAT as initial screen; if positive, confirm with toxin A/B EIA. The diagnosis requires clinically significant diarrhea AND a positive toxin assay.
  • •NAAT alone is not sufficient for diagnosis because it detects toxigenic C. difficile in colonized patients who have diarrhea from another cause. In a multicenter prevalence study, PCR used alone increased reported rates by up to 80% compared with a two-stage EIA-based algorithm.
  • •Diagnostic criteria: diarrhea (≥3 unformed stools per day) plus a positive toxin test (EIA or CCNA) or a positive NAAT with a positive toxin EIA. NAAT-positive/toxin-negative results in diarrheal patients should prompt consideration of alternative causes; these patients may be colonized with another explanation for diarrhea.
  • •Also consider alternative diagnoses: IBD flare, other infectious causes (norovirus, , enteropathogenic E. coli), laxative use, tube feeding, narcotic bowel syndrome, and ischemic colitis. In IBD patients, CDI cannot be distinguished from flare on clinical grounds alone; toxin-based multistep testing is essential.
  • •Assess severity using IDSA criteria: non-severe (diarrhea only, no leukocytosis, normal creatinine), severe (WBC ≥15,000 cells/µL or serum creatinine >1.5 mg/dL), and fulminant (hypotension, ileus, toxic megacolon, or shock). Fulminant CDI carries a 30-40% mortality rate.
  • •Risk stratify for recurrence: age ≥65 years, severe underlying illness, continued need for non-CDI antibiotics, prior CDI episode, and detection of binary toxin (cdtB) are associated with higher recurrence risk. The combination of eosinopenia and binary toxin positivity independently predicts inpatient mortality (OR 7.8).
  • •In special populations, adjust approach: in transplant recipients, CDI occurs in 15% of SOT and 20% of HSCT recipients, with highest rates in the first 30 days. In pediatric patients, community-associated CDI is three times more common than healthcare-associated; fecal calprotectin >500 µg/g may help distinguish infection from carriage.
  • •Consider diagnostic stewardship: clinical decision support alerts reduce inappropriate testing by 45-55% and CDI rates by 30-50%. Near-patient testing (point-of-care NAAT) reduces isolation time and length of stay without compromising accuracy.
  • •Obtain baseline labs: CBC with differential, serum creatinine, electrolytes, and albumin. In patients with suspected fulminant CDI, check lactate, consider abdominal imaging (CT or plain film) to assess for megacolon or perforation.

Diagnosis and Treatment

  • •For an initial episode of non-severe or severe CDI, initiate 200 mg orally twice daily for 10 days as the preferred first-line agent. Fidaxomicin reduces recurrence by approximately half compared with vancomycin and preserves the gut microbiome.
  • •If fidaxomicin is unavailable or cost-prohibitive, use 125 mg orally four times daily for 10 days as an alternative. Vancomycin is effective but associated with higher recurrence rates (~20%) and greater dysbiosis.
  • •Do not use as first-line therapy for initial CDI; it is inferior to vancomycin and fidaxomicin with higher recurrence rates.
  • •For fulminant CDI (hypotension, ileus, toxic megacolon), initiate vancomycin 500 mg orally or by nasogastric tube four times daily plus intravenous metronidazole 500 mg every 8 hours. If ileus is present, add vancomycin 500 mg in 100 mL normal saline per rectum every 6 hours as a retention enema.
  • •For first recurrence, if vancomycin was used initially, switch to fidaxomicin 200 mg BID for 10 days or use a vancomycin taper/pulse regimen (e.g., 125 mg QID for 10 days, then taper).
  • •For patients with multiple recurrences or high risk of recurrence (age ≥65, immunocompromised, severe CDI, ongoing non-CDI antibiotics), add 10 mg/kg IV single dose during the CDI antibiotic course. Bezlotoxumab reduces recurrence from 28% to 17% (NNT=9).
  • •Discontinue the inciting antibiotic(s) whenever possible. If ongoing antimicrobial therapy is required, switch to agents with lowest CDI risk: , , aminoglycosides, or narrow-spectrum β-lactams. Avoid carbapenems, third/fourth-generation cephalosporins, fluoroquinolones, and clindamycin.
  • •Provide aggressive IV crystalloid resuscitation for dehydration. Monitor electrolytes, especially potassium and magnesium. Avoid antiperistaltic agents (opioids, loperamide) as they can precipitate toxic megacolon.
  • •Discontinue proton pump inhibitors unless a clear indication exists. PPI use is associated with increased risk of CDI recurrence (OR 1.42 in IBD patients).
  • •Do not routinely use for prevention or treatment of CDI. A large RCT in ICU patients found no reduction in CDI and a higher rate of probiotic-related infections.
  • •Assess clinical response within 48-72 hours: resolution of diarrhea (≤3 unformed stools per day) and improvement in abdominal pain, fever, and leukocytosis. If no improvement, reassess severity, consider switching antibiotics (e.g., vancomycin to fidaxomicin), add IV metronidazole, or obtain surgical consultation.
  • •For fulminant CDI with toxic megacolon, perforation, or refractory shock, obtain urgent surgical consultation. Subtotal with end ileostomy is the traditional approach; diverting loop ileostomy with colonic lavage is a less morbid alternative and should be considered in selected patients.
  • •For recurrent CDI after multiple episodes (≥2), consider (FMT) or defined microbiota therapeutics such as SER-109 (VOWST) or RBX2660 (REBYOTA). FMT achieves 87.4% clinical resolution with consecutive treatments in immunocompromised patients.
  • •Monitor for complications: VRE colonization, vitamin K deficiency (rare but can cause coagulopathy; treat with IV vitamin K 10 mg), and progression to severe disease. In elderly or malnourished patients with unexplained coagulopathy, suspect vitamin K deficiency.
  • •For patients on concomitant non-CDI antibiotics, consider extending CDI therapy to cover the entire period of antibiotic use, although this is not guideline-recommended. Individualize based on clinical judgment.
  • •In pediatric patients, vancomycin is first-line for initial CDI; fidaxomicin is reserved for recurrent disease. FMT is safe and effective for multiply recurrent cases in children.
  • •In immunocompromised hosts (HCT, SOT, cancer), avoid metronidazole monotherapy; use fidaxomicin or vancomycin. FMT is safe and effective for recurrent CDI and should not be withheld due to immunosuppression alone.

Board Review — High Yield

  • •Toxin B, Sufficient to cause human disease; endogenous anti-TcdB antibodies correlate with protection from recurrence (22% vs 35%).
  • •Binary toxin (CDT), Associated with hypervirulent strains (ribotype 027); independently predicts worse outcomes and higher mortality, especially when combined with eosinopenia (OR 7.8).
  • •Fidaxomicin, Preferred over vancomycin for initial CDI; reduces recurrence from ~17% to ~8% and spares the microbiome.
  • •Bezlotoxumab, Monoclonal antibody against toxin B; reduces recurrence by ~10% when added to standard antibiotics (NNT=9).
  • •Multistep diagnostic algorithm, GDH + toxin EIA preferred over NAAT alone; NAAT-positive/toxin-negative suggests colonization, not infection.
  • •Vancomycin taper, 4-week pulse-and-taper regimen superior to 2-week pulse for preventing recurrence (adjusted RR 0.43).
  • •Fecal microbiota transplantation (FMT), 87.4% resolution with consecutive treatments in recurrent CDI; safe in immunocompromised hosts.
  • •Metronidazole, No longer first-line due to inferior efficacy; reserved for fulminant disease as IV adjunct.
  • •Antibiotic spectrum index, Each unit increase per day of therapy increases CDI risk 1.09-fold; reducing antibiotic intensity is a key stewardship target.
  • •Ribotype 027 (NAP1/BI), Produces binary toxin, has higher fluoroquinolone resistance, and is associated with increased 30-day attributable mortality (RR 1.96).

Deep Dive — Evidence Details

References

  1. [1]

    Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34164674 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  2. [2]

    Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34492699 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  3. [3]

    Drekonja DM, Shaukat A, Huang Y et al.. “A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39271107 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  4. [4]

    Okhuysen PC, Ramesh MS, Louie T et al.. “A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38305378 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  5. [5]

    Feuerstadt P, Chopra T, Knapple W et al.. “PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39180326 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Complications
  6. [6]

    Feuerstadt P, Louie TJ, Lashner B et al.. “SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.” The New England journal of medicine (2022). PMID: 35045228 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  7. [7]

    Dubberke ER, Puckett JT, Obi EN et al.. “Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes.” Open forum infectious diseases (2022). PMID: 36267250 ↗

    L3GUIDELINECited in: Definition, Classification and Causative Organisms
  8. [8]

    Beniwal-Patel P, Stein DJ, Munoz-Price LS. “The Juncture Between Clostridioides difficile Infection and Inflammatory Bowel Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30689770 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications
  9. [9]

    Alshannaq AF, Kates AE, Keating JA et al.. “Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39215602 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  10. [10]

    Lavoie T, Appaneal HJ, LaPlante KL. “Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051964 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  11. [11]

    Anderson SM, Sears CL. “The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051969 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Prognosis and Natural History
  12. [12]

    Le TM, Eubank TA, McKelvey AM et al.. “Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.” Antimicrobial agents and chemotherapy (2024). PMID: 39503488 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  13. [13]

    Myburgh JA, Seppelt IM, Goodman F et al.. “Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial.” JAMA (2022). PMID: 36286097 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  14. [14]

    Louie T, Golan Y, Khanna S et al.. “VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA (2023). PMID: 37060545 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  15. [15]

    Khanna S, Allegretti JR, Hashash JG et al.. “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.” Gastroenterology (2026). PMID: 42138670 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prevention and Infection Control
  16. [16]

    Jo J, Carlson TJ, Hu C et al.. “Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.” The Journal of antimicrobial chemotherapy (2025). PMID: 40796204 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  17. [17]

    Di Bella S, Sanson G, Monticelli J et al.. “Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.” Clinical microbiology reviews (2024). PMID: 38421181 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  18. [18]

    Yadegar A, Bar-Yoseph H, Monaghan TM et al.. “Fecal microbiota transplantation: current challenges and future landscapes.” Clinical microbiology reviews (2024). PMID: 38717124 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  19. [19]

    Beebe MA, Sorg JA. “An update on Clostridioides difficile population structure and genomics.” Clinical microbiology reviews (2026). PMID: 41914740 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  20. [20]

    Tang L, Xie P, Wang H et al.. “The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions.” Clinical microbiology reviews (2025). PMID: 41263574 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  21. [21]

    Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  22. [22]

    Veve MP, Kenney RM, Aljundi AM et al.. “Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.” Antimicrobial agents and chemotherapy (2025). PMID: 40035548 ↗

    L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History, Special Hosts and Populations
  23. [23]

    DeFilipp Z, Bloom PP, Torres Soto M et al.. “Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.” The New England journal of medicine (2019). PMID: 31665575 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Complications
  24. [24]

    Butler MS, Gigante V, Sati H et al.. “Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.” Antimicrobial agents and chemotherapy (2022). PMID: 35007139 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  25. [25]

    Rode AA, Duboc H, Lamazière A et al.. “Re-establishing bile acid composition after treatment of recurrent Clostridioides difficile infection with fecal microbiota transplantation compared with oral vancomycin or a 12-strain bacterial mixture.” Gut microbes (2026). PMID: 41997890 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  26. [26]

    Chernova VO, van Prehn J, Groenewegen B et al.. “Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.” United European gastroenterology journal (2026). PMID: 42283215 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications
  27. [27]

    Duricek M, Bartos H, Halmova K et al.. “ESBL positivity as an independent predictor of Clostridioides difficile infection: a retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42070626 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  28. [28]

    Savage TJ, Butler AM, Kronman MP et al.. “Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults.” JAMA (2026). PMID: 41999289 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History
  29. [29]

    Gong J-J, Huang I-H, Hung Y et al.. “Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.” Antimicrobial agents and chemotherapy (2025). PMID: 40525407 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  30. [30]

    Webb BJ, Subramanian A, Lopansri B et al.. “Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.” Antimicrobial agents and chemotherapy (2020). PMID: 31964789 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  31. [31]

    Madden GR, Petri WA, Costa DVS et al.. “Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.” Antimicrobial agents and chemotherapy (2022). PMID: 35727061 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  32. [32]

    Kester JC, Brubaker DK, Velazquez J et al.. “Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.” Antimicrobial agents and chemotherapy (2020). PMID: 31988098 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  33. [33]

    Bassères E, Eubank TA, Begum K et al.. “Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.” Antimicrobial agents and chemotherapy (2024). PMID: 38364016 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  34. [34]

    Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 31932379 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  35. [35]

    Rashid T, Haghighi F, Hasan I et al.. “Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms.” Antimicrobial agents and chemotherapy (2019). PMID: 31611365 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prevention and Infection Control
  36. [36]

    Buckley AM, Moura IB, Altringham J et al.. “The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection.” The Journal of antimicrobial chemotherapy (2021). PMID: 34561709 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment
  37. [37]

    Brenciani A, Massacci FR, Albini E et al.. “Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy.” The Journal of antimicrobial chemotherapy (2025). PMID: 40556560 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  38. [38]

    Duricek M, Halmova K, Krutova M et al.. “Is shorter also better in the treatment of Clostridioides difficile infection?” The Journal of antimicrobial chemotherapy (2024). PMID: 38661207 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  39. [39]

    Ranganath N, Tabaja H, Nair VO et al.. “Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40470775 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History
  40. [40]

    Schwanbeck J, Riedel T, Laukien F et al.. “Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.” The Journal of antimicrobial chemotherapy (2019). PMID: 30247587 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup
  41. [41]

    Saydan S, Schwab F, Holstiege J et al.. “Surveillance of Clostridioides difficile on hospital admission and outpatient antibiotic use in Germany-a 9 year ecological analysis.” The Journal of antimicrobial chemotherapy (2025). PMID: 39821312 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  42. [42]

    Eyre DW, Shaw R, Adams H et al.. “WGS to determine the extent of Clostridioides difficile transmission in a high incidence setting in North Wales in 2015.” The Journal of antimicrobial chemotherapy (2019). PMID: 30561656 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment
  43. [43]

    Orzechowski D, Mroczkowska A, Bryła A et al.. “Clinical Considerations of Amikacin Pharmacotherapy in Adults-A Narrative Review with Focus on Safety and TDM.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353658 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  44. [44]

    Lietz S, Barth H. “Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin.” Archives of toxicology (2026). PMID: 41991729 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  45. [45]

    Boton N, Patel PK, Beekmann SE et al.. “Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey.” Open forum infectious diseases (2025). PMID: 40599494 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control
  46. [46]

    Dubberke ER, Li Q, Obi EN et al.. “A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 39355263 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  47. [47]

    Jitmuang A, Lertlaksameewilai P, Poorichitiporn A et al.. “Multiplex Gastrointestinal Panel Testing in Hospitalized Patients With Acute Diarrhea in Thailand.” Open forum infectious diseases (2024). PMID: 38962524 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  48. [48]

    Chua HC, Eubank TA, Lee A et al.. “Defining Fulminant Clostridioides difficile Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion.” Open forum infectious diseases (2025). PMID: 39896986 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  49. [49]

    Carlson TJ, Gonzales-Luna AJ, Nebo K et al.. “Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection.” Open forum infectious diseases (2020). PMID: 33209956 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  50. [50]

    Yin J, Kociolek LK, Same RG et al.. “Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections.” Open forum infectious diseases (2019). PMID: 31950069 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  51. [51]

    Skinner AM, Petrella L, Siddiqui F et al.. “Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain.” Emerging infectious diseases (2020). PMID: 31961290 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  52. [52]

    Conlon-Bingham GM, Aldeyab M, Scott M et al.. “Effects of Antibiotic Cycling Policy on Incidence of Healthcare-Associated MRSA and Clostridioides difficile Infection in Secondary Healthcare Settings.” Emerging infectious diseases (2019). PMID: 30561306 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control
  53. [53]

    Du T, Silva A, Choi KB et al.. “Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015-2022.” Emerging infectious diseases (2025). PMID: 40439410 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  54. [54]

    Rizzardi K, Norén T, Aspevall O et al.. “National Surveillance for Clostridioides difficile Infection, Sweden, 2009-2016.” Emerging infectious diseases (2018). PMID: 30124193 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  55. [55]

    Kim MH, Kim J, Ra H et al.. “Identifying Contact Time Required for Secondary Transmission of Clostridioides difficile Infections by Using Real-Time Locating System.” Emerging infectious diseases (2024). PMID: 38666567 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History
  56. [56]

    Sandhu A, Tillotson G, Polistico J et al.. “Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.” Emerging infectious diseases (2020). PMID: 32441243 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  57. [57]

    Zambelli G, Masetti M, Rasmi S et al.. “Restoring Microbial Balance: Clinical Applications, Challenges, and Future Directions of Fecal Microbiota Transplantation in Pediatric Disorders.” Microorganisms (2026). PMID: 42354867 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  58. [58]

    Raphaël É, Huynh S, Blez D et al.. “Ceftriaxone versus cefotaxime: a scoping review of resistance selection, Clostridioides difficile risk, economic implications and environmental impacts.” Infectious diseases now (2026). PMID: 42013917 ↗

    L2REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  59. [59]

    Bayode MT, Olawale OE, Olusola-Makinde OO. “Divergent mechanistic pathways of diarrheagenic bacterial infections at the host-microbiota interface: a review.” Archives of microbiology (2026). PMID: 42007992 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  60. [60]

    Patel MJ, O'Brien J. “Epidemiologic Trends in Clostridioides difficile Infection Among U.S. Emergency Department Patients, 2014-2024.” American journal of infection control (2026). PMID: 42431317 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control
  61. [61]

    Prosty C, Hanula R, Katergi K et al.. “Clinical Outcomes and Management of NAAT-Positive/Toxin-Negative Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37648251 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  62. [62]

    Donskey CJ, Dubberke ER, Klein NP et al.. “CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39180325 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  63. [63]

    Kelly CP, Poxton IR, Shen J et al.. “Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31628838 ↗

    L2RCTCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  64. [64]

    Louie T, Ribble W, Boccumini L et al.. “Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.” The Lancet. Infectious diseases (2026). PMID: 41581516 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  65. [65]

    de Bruyn G, Gordon DL, Steiner T et al.. “Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.” The Lancet. Infectious diseases (2020). PMID: 32946836 ↗

    L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications, Prognosis and Natural History
  66. [66]

    Edlund C, Ternhag A, Skoog Ståhlgren G et al.. “The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.” The Lancet. Infectious diseases (2021). PMID: 34756180 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  67. [67]

    Karlowsky JA, Steenbergen J, Zhanel GG. “Microbiology and Preclinical Review of Omadacycline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367743 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  68. [68]

    Lomeli BK, Galbraith H, Schettler J et al.. “Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.” Antimicrobial agents and chemotherapy (2019). PMID: 31685472 ↗

    L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications
  69. [69]

    Guery B, Georgopali A, Karas A et al.. “Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.” The Journal of antimicrobial chemotherapy (2020). PMID: 31960058 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  70. [70]

    Fitzpatrick F, Safdar N, van Prehn J et al.. “How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?” The Lancet. Infectious diseases (2022). PMID: 35617982 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  71. [71]

    Jo J, Hu C, Horvath TD et al.. “Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.” Antimicrobial agents and chemotherapy (2025). PMID: 39819014 ↗

    L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis
  72. [72]

    Kociolek LK, Espinosa RO, Gerding DN et al.. “Natural Clostridioides difficile Toxin Immunization in Colonized Infants.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31253983 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Complications, Prevention and Infection Control
  73. [73]

    Redmond SN, Cadnum JL, Jencson AL et al.. “Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036727 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  74. [74]

    Lin Q, Pollock NR, Banz A et al.. “Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31400280 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  75. [75]

    Villafuerte Gálvez JA, Pollock NR, Alonso CD et al.. “Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35906836 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Complications
  76. [76]

    Schechner V, Fallach N, Braun T et al.. “Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study.” The Journal of antimicrobial chemotherapy (2021). PMID: 33969419 ↗

    L3COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  77. [77]

    Marchandin H, Anjou C, Poulen G et al.. “In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2023). PMID: 37352110 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship
  78. [78]

    Abou Chakra CN, Gagnon A, Lapointe S et al.. “The Strain and the Clinical Outcome of Clostridioides difficile Infection: A Meta-analysis.” Open forum infectious diseases (2024). PMID: 38524230 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  79. [79]

    Zilberberg MD, Nathanson BH, Ditch K et al.. “Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study.” Open forum infectious diseases (2019). PMID: 31858017 ↗

    L3COHORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  80. [80]

    Nichols WW, Bradford PA, Stone GG. “The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.” The Journal of antimicrobial chemotherapy (2023). PMID: 36883356 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  81. [81]

    Wilcox MH, McGovern BH, Hecht GA. “The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.” Open forum infectious diseases (2020). PMID: 32405509 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Complications
  82. [82]

    Bansal D, Pahil S, Chatterjee A et al.. “Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.” Therapeutic advances in gastroenterology (2026). PMID: 42136876 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis
  83. [83]

    Wondimkun YA, Inacio MC, Lekkas P et al.. “Trends in microbiology testing in Australian long-term care facilities: national cohort study.” BMC infectious diseases (2026). PMID: 42226143 ↗

    L4COHORTCited in: Microbiology and Pathogenesis
  84. [84]

    Lee SH, Kim TY, Huh HJ et al.. “Clinical outcomes of toxin-positive versus toxin-negative/NAAT-positive Clostridioides difficile infection in South Korea: a single-center retrospective cohort study.” BMC infectious diseases (2026). PMID: 42168920 ↗

    L3COHORTCited in: Microbiology and Pathogenesis
  85. [85]

    Liu Y, Ma L, Cheng J et al.. “Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.” Antimicrobial agents and chemotherapy (2023). PMID: 37223895 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  86. [86]

    Costa DVS, Pham NVS, Hays RA et al.. “Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35861541 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification
  87. [87]

    Kaple CE, Redmond SN, Cadnum JL et al.. “Clinical failure of an extended-pulsed fidaxomicin regimen associated with emergence of a Clostridioides difficile isolate with reduced fidaxomicin susceptibility in an elderly man.” Antimicrobial agents and chemotherapy (2026). PMID: 42080560 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  88. [88]

    Abutaleb NS, Seleem MN. “Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32253206 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  89. [89]

    Lew T, Putsathit P, Sohn KM et al.. “Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.” Antimicrobial agents and chemotherapy (2020). PMID: 32393487 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  90. [90]

    Harris HC, Best EL, Normington C et al.. “Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics.” Antimicrobial agents and chemotherapy (2020). PMID: 33139292 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  91. [91]

    Budi N, Godfrey JJ, Safdar N et al.. “Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile.” Antimicrobial agents and chemotherapy (2021). PMID: 33649111 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  92. [92]

    Thorpe CM, McDermott LA, Tran MK et al.. “U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.” Antimicrobial agents and chemotherapy (2019). PMID: 31085514 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  93. [93]

    Aoki K, Takeda S, Miki T et al.. “Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.” Antimicrobial agents and chemotherapy (2019). PMID: 31527041 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  94. [94]

    Hutton ML, Pehlivanoglu H, Vidor CJ et al.. “Repurposing auranofin as a Clostridioides difficile therapeutic.” The Journal of antimicrobial chemotherapy (2020). PMID: 31642901 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  95. [95]

    Putsathit P, Hong S, George N et al.. “Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.” The Journal of antimicrobial chemotherapy (2021). PMID: 33895826 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  96. [96]

    Murray B, Wolfe C, Marra A et al.. “In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32285102 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  97. [97]

    Escudero-Sánchez R, Rubio Martín E, Vizcarra P et al.. “Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36861316 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  98. [98]

    Simpson M, Bilverstone T, Leslie J et al.. “Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model.” Open forum infectious diseases (2023). PMID: 36895287 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  99. [99]

    Young MK, Leslie JL, Madden GR et al.. “Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease.” Open forum infectious diseases (2022). PMID: 35146046 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  100. [100]

    Carlson TJ, Endres BT, Le Pham J et al.. “Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2020). PMID: 31993458 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
  101. [101]

    Anderson SM, Cing Z, Drewes JL et al.. “Clostridioides difficile Detection in a Human CRC Cohort.” Open forum infectious diseases (2026). PMID: 41969757 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  102. [102]

    Hilt EE, Vaughn BP, Galdys AL et al.. “Impact of the Reverse 2-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients.” Open forum infectious diseases (2024). PMID: 38756762 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  103. [103]

    Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Open forum infectious diseases (2019). PMID: 31890725 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations
  104. [104]

    Wilcox MH, Cornely OA, Guery B et al.. “Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.” Open forum infectious diseases (2019). PMID: 31723569 ↗

    L1OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation
  105. [105]

    Pender M, Throneberry SK, Grisel N et al.. “Syndromic Panel Testing Among Patients With Infectious Diarrhea: The Challenge of Interpreting Clostridioides difficile Positivity on a Multiplex Molecular Panel.” Open forum infectious diseases (2023). PMID: 37711280 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  106. [106]

    Widmer AF, Frei R, Kuijper EJ et al.. “Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland.” Emerging infectious diseases (2020). PMID: 32946368 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  107. [107]

    Iorgoni V, Stanga L, Nistor P et al.. “Fatal Systemic Infection Caused by Multidrug-Resistant Clostridioides difficile in a Domestic Rabbit: A Comprehensive Case Analysis.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353696 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  108. [108]

    Wu L, Li Z, Zhu J et al.. “Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.” Microorganisms (2026). PMID: 42354799 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  109. [109]

    Mirjalili S, Hosseini Hooshiar M, Abbasabadarabi S et al.. “Host immunity and recurrent Clostridioides difficile infection: a comprehensive review.” Pathogens and global health (2026). PMID: 42304879 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  110. [110]

    Zhao M, Wen B, Ouyang Z et al.. “Parabacteroides distasonis alleviates Clostridioides difficile infection in mice while modulating secondary bile acids.” Virulence (2026). PMID: 42402046 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  111. [111]

    Queraltó C, Rodríguez J, Escobar F et al.. “Cytoplasmic membrane vesicles from Clostridioides difficile R20291 are remodeled by osmotic stress.” Frontiers in microbiology (2026). PMID: 42388301 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  112. [112]

    Fu M, Hu L, Han K et al.. “The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2025). PMID: 40122092 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Complications
  113. [113]

    Kelly CR, Allegretti JR. “Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051967 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control
  114. [114]

    Slimings C, Riley TV. “Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.” The Journal of antimicrobial chemotherapy (2021). PMID: 33787887 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  115. [115]

    Carlson TJ, Gonzales-Luna AJ. “Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32696044 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Prognosis and Natural History, Prevention and Infection Control
  116. [116]

    Dulhunty JM, Brett SJ, De Waele JJ et al.. “Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.” JAMA (2024). PMID: 38864155 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  117. [117]

    Arabi YM, Alsaawi A, Alzahrani M et al.. “Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial.” JAMA (2025). PMID: 39658862 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  118. [118]

    Sauvat L, Verhoeven PO, Gagnaire J et al.. “Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.” Clinical microbiology reviews (2024). PMID: 39120140 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  119. [119]

    Gargis AS, Karlsson M, Paulick AL et al.. “Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36208202 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  120. [120]

    Perry DA, Shirley D, Micic D et al.. “External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34459885 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications, Prognosis and Natural History
  121. [121]

    Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History
  122. [122]

    Raponi M, Mancini R, Martinelli S et al.. “Infection prevention, control and antimicrobial stewardship measures in intensive in-patient rehabilitation setting: a systematic review.” Antimicrobial resistance and infection control (2026). PMID: 42192548 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  123. [123]

    Oltolini C, Piekarska A, Signori A et al.. “Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).” Blood reviews (2026). PMID: 42106226 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  124. [124]

    Wei Q, Cai Y, Lu G et al.. “Prediction models for recurrence and mortality in patients with clostridioides difficile infection: a systematic review and meta-analysis.” The Journal of hospital infection (2026). PMID: 42081949 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  125. [125]

    Landivar MC, Hartmann Rost I, Carvalho Kilson A et al.. “Efficacy of fluoroquinolone prophylaxis during induction phase in children with acute lymphoblastic leukemia: a systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 42065773 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations
  126. [126]

    Zhao Y, He X, Hu Y et al.. “Impact of the COVID-19 pandemic on the incidence of Clostridioides difficile infection based on hospital surveillance data: a systematic review and meta-analysis.” Antimicrobial resistance and infection control (2026). PMID: 41933426 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Prevention and Infection Control
  127. [127]

    Wei Q, Lu G, Diao H et al.. “The Incidence and Risk Factors of Antibiotic-Associated Diarrhea in Critically Ill Patients: A Systematic Review and Meta-Analysis.” Journal of gastroenterology and hepatology (2026). PMID: 41804814 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  128. [128]

    Skjøt-Arkil H, Rune Nanthan K, Chen M et al.. “Carrier prevalence of Clostridioides difficile in emergency departments and the association of prior antibiotic consumption: a combined cross-sectional and nested case-control study.” The Journal of antimicrobial chemotherapy (2023). PMID: 37409612 ↗

    L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
  129. [129]

    Lopez-Alcalde J, Mateos-Mazón M, Oliveira Conterno L et al.. “Decontamination of environmental surfaces in hospitals to reduce hospital-acquired infections: a systematic review.” Infection prevention in practice (2026). PMID: 41883627 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  130. [130]

    Guh AY, Mu Y, Winston LG et al.. “Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.” The New England journal of medicine (2020). PMID: 32242357 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  131. [131]

    Magill SS, O'Leary E, Janelle SJ et al.. “Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.” The New England journal of medicine (2018). PMID: 30380384 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  132. [132]

    Chen YC, Kuo YC, Chen MC et al.. “Case-Control Study of Clostridium innocuum Infection, Taiwan.” Emerging infectious diseases (2022). PMID: 35195517 ↗

    L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  133. [133]

    Okafor CM, Clogher P, Olson D et al.. “Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.” Emerging infectious diseases (2023). PMID: 37081745 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  134. [134]

    Daniel F, Abdallah B, Chaitou AR et al.. “Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study.” Surgical endoscopy (2026). PMID: 42257924 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  135. [135]

    Rhodes NJ, Jozefczyk CC, Moore WJ et al.. “Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2021). PMID: 33875439 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  136. [136]

    Snydman DR, McDermott LA, Thorpe CM et al.. “A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021.” Antimicrobial agents and chemotherapy (2023). PMID: 37728368 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  137. [137]

    Zhang J, Chen L, Gomez-Simmonds A et al.. “Antibiotic-Specific Risk for Community-Acquired Clostridioides difficile Infection in the United States from 2008 to 2020.” Antimicrobial agents and chemotherapy (2022). PMID: 36377887 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  138. [138]

    Wieczorkiewicz JT, Skinner AM, Cheknis A et al.. “Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.” Antimicrobial agents and chemotherapy (2024). PMID: 38953622 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  139. [139]

    Arensman K, Shields M, Beganovic M et al.. “Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32839223 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  140. [140]

    Karp J, Edman-Wallér J, Toepfer M et al.. “Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals.” The Journal of antimicrobial chemotherapy (2019). PMID: 30358837 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  141. [141]

    Tydeman F, Craine N, Kavanagh K et al.. “Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales.” The Journal of antimicrobial chemotherapy (2021). PMID: 34151964 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  142. [142]

    Moreels N, Boven A, Gressani O et al.. “The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.” The Journal of antimicrobial chemotherapy (2024). PMID: 38267263 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  143. [143]

    Yamamoto S, Shiroshita A, Kataoka Y et al.. “Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.” Open forum infectious diseases (2025). PMID: 40134633 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  144. [144]

    Ilett EE, Helleberg M, Reekie J et al.. “Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.” Open forum infectious diseases (2019). PMID: 30949533 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  145. [145]

    Rao K, Garey KW. “From Chaos to Clarity? The Quest for Effective Probiotics in Antibiotic-Associated Diarrhea.” Open forum infectious diseases (2024). PMID: 39529940 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control
  146. [146]

    Olsen MA, Keller MR, Stwalley D et al.. “Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37547851 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  147. [147]

    Li X, Xiao F, Wang X et al.. “Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children.” Open forum infectious diseases (2024). PMID: 39319090 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control
  148. [148]

    Sanchez E, Krantz EM, Escobar ZK et al.. “Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.” Open forum infectious diseases (2024). PMID: 39450393 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  149. [149]

    Tartof SY, Schmidt MA, Contreras R et al.. “Burden of Medically Attended Diarrhea and Outpatient Clostridioides difficile Infection Among Persons in 2 Large Integrated Healthcare Settings, 2016-2021.” Open forum infectious diseases (2024). PMID: 38250203 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  150. [150]

    Williams MJ, Atienza S, Franzen E et al.. “Evaluation of Primary Oral Vancomycin Prophylaxis Against Clostridioides difficile Infection During Autologous Stem Cell Transplantation.” Open forum infectious diseases (2024). PMID: 39498172 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Prevention and Infection Control
  151. [151]

    Johnson TM, Howard AH, Miller MA et al.. “Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients.” Open forum infectious diseases (2021). PMID: 34262988 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  152. [152]

    Moloney G, Eyre DW, Mac Aogáin M et al.. “Human and Porcine Transmission of Clostridioides difficile Ribotype 078, Europe.” Emerging infectious diseases (2021). PMID: 34423760 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  153. [153]

    Du T, Choi KB, Silva A et al.. “Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019.” Emerging infectious diseases (2022). PMID: 35470794 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  154. [154]

    Guo CLT, Kwong TNY, Mak JWY et al.. “Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong.” Emerging infectious diseases (2021). PMID: 34812719 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  155. [155]

    Miller AC, Arakkal AT, Sewell DK et al.. “Risk for Asymptomatic Household Transmission of Clostridioides difficile Infection Associated with Recently Hospitalized Family Members.” Emerging infectious diseases (2022). PMID: 35447064 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  156. [156]

    Capone D, Bakare T, Barker T et al.. “Risk Factors for Enteric Pathogen Exposure among Children in Black Belt Region of Alabama, USA.” Emerging infectious diseases (2023). PMID: 37987604 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  157. [157]

    Ramirez JA, Angulo FJ, Carrico RM et al.. “Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019-20201.” Emerging infectious diseases (2023). PMID: 37080953 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  158. [158]

    Dunn AN, Radakovich N, Ancker JS et al.. “The Impact of Clinical Decision Support Alerts on Clostridioides difficile Testing: A Systematic Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32060501 ↗

    L2SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Complications
  159. [159]

    Doolan CP, Sahragard B, Leal J et al.. “Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36718646 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  160. [160]

    Doolan CP, Louie T, Lata C et al.. “Latent Class Analysis for the Diagnosis of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33053174 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
  161. [161]

    Rock C, Abosi O, Bleasdale S et al.. “Clinical Decision Support Systems to Reduce Unnecessary Clostridioides difficile Testing Across Multiple Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35100620 ↗

    L2OTHERCited in: Clinical Presentation
  162. [162]

    Kelly CP, Chen X, Williams D et al.. “Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31211839 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
  163. [163]

    Guh AY, Hatfield KM, Winston LG et al.. “Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30615074 ↗

    L3OTHERCited in: Clinical Presentation, Special Hosts and Populations
  164. [164]

    Turner NA, Krishnan J, Nelson A et al.. “Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37279965 ↗

    L2OTHERCited in: Clinical Presentation
  165. [165]

    Yan AP, Yi M, Patel P et al.. “Use of Electronic Health Records to Benchmark Clinical Practice Guideline-Consistent Care in Pediatric Oncology.” JCO clinical cancer informatics (2026). PMID: 41886707 ↗

    L5GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Prevention and Infection Control, Special Hosts and Populations
  166. [166]

    Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications
  167. [167]

    McKay V, Malone S, Tetteh E et al.. “Facilitation as an effective strategy to reduce excessive antibiotic prophylaxis in Children's hospitals: A stepped-wedge cluster randomized controlled trial.” Implementation science : IS (2025). PMID: 41121325 ↗

    L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prevention and Infection Control, Special Hosts and Populations
  168. [168]

    Salvador BC, Gomes DL, Araujo AGS et al.. “Systematic review: Accuracy of diagnostic methods for Clostridioides difficile infection.” Anaerobe (2026). PMID: 41833705 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup
  169. [169]

    Wang C, Gao H, Zhu C et al.. “Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses.” BMJ evidence-based medicine (2026). PMID: 42303374 ↗

    L1SR_OBSCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History, Prevention and Infection Control
  170. [170]

    Aràjol C, González Suárez B, Bonilla Moreno M et al.. “Clostridioides difficile infection: Position paper of the Catalan Society of Gastroenterology.” Gastroenterologia y hepatologia (2026). PMID: 41547475 ↗

    L1GUIDELINECited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  171. [171]

    Kozák M, Majoros L, Panyiczki Z et al.. “Severe vitamin K deficiency-associated coagulopathy triggered by Clostridioides difficile infection and antibiotic-associated dysbiosis: A case report and literature review.” Infection (2026). PMID: 41563580 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  172. [172]

    AlAwadhi HK, Hyesoo Chang N, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  173. [173]

    Guh AY, Li R, Korhonen L et al.. “Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences.” Open forum infectious diseases (2024). PMID: 38577028 ↗

    L3OTHERCited in: Clinical Presentation
  174. [174]

    Harrison CJ, Hassan F, Lee B et al.. “Multiplex PCR Pathogen Detection in Acute Gastroenteritis Among Hospitalized US Children Compared With Healthy Controls During 2011-2016 in the Post-Rotavirus Vaccine Era.” Open forum infectious diseases (2021). PMID: 34988246 ↗

    L3OTHERCited in: Clinical Presentation
  175. [175]

    Curry SR, Hecker MT, O'Hagan J et al.. “Natural History of Clostridioides difficile Colonization and Infection Following New Acquisition of Carriage in Healthcare Settings: A Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36905149 ↗

    L2COHORTCited in: Diagnosis and Workup, Prognosis and Natural History
  176. [176]

    Darkoh C, Keita K, Odo C et al.. “Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35016207 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  177. [177]

    Crotty M, Devall H, Cook N et al.. “Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.” Open forum infectious diseases (2024). PMID: 39257675 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  178. [178]

    Wilcox MH, Rahav G, Dubberke ER et al.. “Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.” Open forum infectious diseases (2019). PMID: 31375837 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup
  179. [179]

    Barbero AM, Moriconi ND, Palma S et al.. “Epidemiology of Clostridioides difficile Infection in Argentina and Associated Risk Factors Evaluated Through a Meta-Analysis.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353652 ↗

    L3SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  180. [180]

    Begum K, Bassères E, Miranda J et al.. “In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.” Antimicrobial agents and chemotherapy (2020). PMID: 32513796 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  181. [181]

    Oka D, Yamaya N, Kuno T et al.. “In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.” Antimicrobial agents and chemotherapy (2021). PMID: 33495229 ↗

    L5OTHERCited in: Diagnosis and Workup, Complications
  182. [182]

    Wickramage I, Spigaglia P, Sun X. “Mechanisms of antibiotic resistance of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2021). PMID: 34297842 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  183. [183]

    Skinner AM, Petrella LA, Cheknis A et al.. “Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials.” The Journal of antimicrobial chemotherapy (2023). PMID: 37279600 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  184. [184]

    Karczewski J, Brown CM, Maezato Y et al.. “Efficacy of a novel lantibiotic, CMB001, against MRSA.” The Journal of antimicrobial chemotherapy (2021). PMID: 33582800 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  185. [185]

    Youenou B, Martins Simoes P, Tristan A et al.. “Linezolid resistance: detection of the cfr(B) gene in French clinical MRSA strains.” The Journal of antimicrobial chemotherapy (2023). PMID: 36509546 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  186. [186]

    Bassères E, Begum K, Lancaster C et al.. “In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32719870 ↗

    L4OTHERCited in: Diagnosis and Workup
  187. [187]

    Oka D, Changkwanyeun R, Yamaguchi T et al.. “In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.” The Journal of antimicrobial chemotherapy (2022). PMID: 36101508 ↗

    L4OTHERCited in: Diagnosis and Workup
  188. [188]

    Cheknis A, Devaris D, Chesnel L et al.. “Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.” The Journal of antimicrobial chemotherapy (2020). PMID: 32747931 ↗

    L2OTHERCited in: Diagnosis and Workup
  189. [189]

    Vernon JJ, Wilcox MH, Freeman J. “Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness.” The Journal of antimicrobial chemotherapy (2019). PMID: 30590496 ↗

    L5OTHERCited in: Diagnosis and Workup
  190. [190]

    Itogawa K, Narumoto O, Takeda K et al.. “Continuation of anti-tuberculosis therapy after Clostridioides difficile infection: a retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42296592 ↗

    L2COHORTCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  191. [191]

    Jiang X, Wu L, Duan S et al.. “Long-Term Antibiotic-Driven Gut Microbiota Disruption Promotes Toxigenic Clostridioides difficile Proliferation: A Four-Year Retrospective Study of a Single ICU Patient.” Infection and drug resistance (2026). PMID: 41859067 ↗

    L4COHORTCited in: Diagnosis and Workup
  192. [192]

    Lee MM, Reske KA, Hink T et al.. “Relationship Between Clostridioides difficile Stool Concentration, Nucleic Acid Amplification Test Results, and Environmental Contamination.” Open forum infectious diseases (2026). PMID: 41929670 ↗

    L4OTHERCited in: Diagnosis and Workup
  193. [193]

    Yetsko A, Draper HM, Eid K et al.. “Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females.” Open forum infectious diseases (2023). PMID: 37779597 ↗

    L2OTHERCited in: Diagnosis and Workup
  194. [194]

    Advani SD, Gao CA, Datta R et al.. “Knowledge and Practices of Physicians and Nurses Related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines.” Open forum infectious diseases (2019). PMID: 31375836 ↗

    L4OTHERCited in: Diagnosis and Workup
  195. [195]

    Wo S, Dubrovskaya Y, Siegfried J et al.. “Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia.” Open forum infectious diseases (2020). PMID: 33511221 ↗

    L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications
  196. [196]

    Smits WK, Harmanus C, Sanders IMJG et al.. “Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates.” Emerging infectious diseases (2022). PMID: 36286226 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  197. [197]

    Pipitò L, Anastasia A, D'Agati G et al.. “Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection in a critically ill patient with concomitant Clostridioides difficile colitis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42235915 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  198. [198]

    Maeda M, Mori N, Hiraide M et al.. “Evaluation of Antibiotic Use Metrics as Predictors of Clostridioides difficile Infection Onset: A Single-Center, Case-Control Study Assessing the Days of Therapy and the Days of Antibiotic Spectrum Coverage.” Biological & pharmaceutical bulletin (2026). PMID: 41765474 ↗

    L3CASE_CONTROLCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  199. [199]

    Alzahrani N, Alfaouri H, Al Johani S. “Gastrointestinal pathogens detected by a multiplex PCR panel in a tertiary care center in Riyadh, Saudi Arabia (2023-2024).” Frontiers in public health (2026). PMID: 42317984 ↗

    L4OTHERCited in: Diagnosis and Workup
  200. [200]

    Patterson WM, Fajnzylber J, Nero N et al.. “Diagnostic prediction models to identify patients at risk for healthcare-facility-onset Clostridioides difficile: A systematic review of methodology and reporting.” Infection control and hospital epidemiology (2023). PMID: 37665104 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  201. [201]

    Friedrichs A, Wenz R, Pape D et al.. “The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study.” Infection (2025). PMID: 40569348 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  202. [202]

    Chen JH, Chiu CH, Chen CC et al.. “Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study.” Biomedicines (2024). PMID: 39061970 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  203. [203]

    Chen W, Liu Y, Zhang Y et al.. “Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.” BMC gastroenterology (2024). PMID: 39448963 ↗

    L1SR_OBSCited in: Severity Assessment and Risk Stratification
  204. [204]

    Wen BJ, Te LG, Liu XX et al.. “The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.” Frontiers in physiology (2022). PMID: 35991191 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  205. [205]

    Li J, Yang J, Ouyang Z et al.. “Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: A retrospective study.” Journal of global antimicrobial resistance (2025). PMID: 40287014 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  206. [206]

    Le PH, Chen CL, Kuo CJ et al.. “Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study.” The Kaohsiung journal of medical sciences (2025). PMID: 40091757 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  207. [207]

    Tariq R, Sethi A, Arunachalam S et al.. “Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD).” The American journal of gastroenterology (2026). PMID: 41562450 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  208. [208]

    Rao K, Zhao Q, Bell J et al.. “An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37797310 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  209. [209]

    Llewelyn MJ, Budgell EP, Laskawiec-Szkonter M et al.. “Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.” The Lancet. Infectious diseases (2022). PMID: 36206793 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  210. [210]

    Young PJ, Bagshaw SM, Forbes AB et al.. “Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.” JAMA (2020). PMID: 31950977 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control
  211. [211]

    Johnstone J, Meade M, Lauzier F et al.. “Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.” JAMA (2021). PMID: 34546300 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History
  212. [212]

    Fischer M, Vaughn BP, Peery AF et al.. “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42383946 ↗

    L5GUIDELINECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prevention and Infection Control
  213. [213]

    Nhu NTQ, Young VB. “The Relationship Between the Microbiome and Antimicrobial Resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051965 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  214. [214]

    Alonso CD, Tillotson GS, Bidell MR et al.. “Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.” Open forum infectious diseases (2025). PMID: 40177588 ↗

    L2TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Complications
  215. [215]

    Phillips EC, Warren CA, Ma JZ et al.. “Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35647645 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  216. [216]

    Ordás I, Caballol B, Giordano A et al.. “Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.” Gastroenterologia y hepatologia (2026). PMID: 42248446 ↗

    L5GUIDELINECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  217. [217]

    Gonzales-Luna AJ, Skinner AM, Alonso CD et al.. “Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.” The Lancet. Infectious diseases (2023). PMID: 37062301 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  218. [218]

    Naz F, Petri WA. “Host Immunity and Immunization Strategies for Clostridioides difficile Infection.” Clinical microbiology reviews (2023). PMID: 37162338 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control
  219. [219]

    Allegretti JR, Mullish BH, Kelly C et al.. “The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.” Lancet (London, England) (2019). PMID: 31379333 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  220. [220]

    Berkefeld A, Berger FK, Gärtner BC et al.. “Clostridioides (Clostridium) difficile Pacemaker Infection.” Open forum infectious diseases (2020). PMID: 33324719 ↗

    L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control
  221. [221]

    Phan JR, Do DM, Truong MC et al.. “An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.” Antimicrobial agents and chemotherapy (2021). PMID: 34780262 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  222. [222]

    Hu X, Dong R, Huang S et al.. “CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.” Antimicrobial agents and chemotherapy (2023). PMID: 37052498 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  223. [223]

    Bishop EJ, Tiruvoipati R. “Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.” The Journal of antimicrobial chemotherapy (2022). PMID: 36441203 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  224. [224]

    Bassetti M, Cascio A, De Rosa FG et al.. “Management of Clostridioides difficile infection: an Italian Delphi consensus.” The Journal of antimicrobial chemotherapy (2024). PMID: 39008427 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  225. [225]

    O'Sullivan CE. “Antimicrobial stewardship failure: time for a new model.” The Journal of antimicrobial chemotherapy (2020). PMID: 32068845 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  226. [226]

    Ronda M, Padullés A, Grau I et al.. “Impact of a prospective audit and feedback antimicrobial stewardship programme on carbapenem consumption: a quasi-experimental study (IPANEMA study).” The Journal of antimicrobial chemotherapy (2023). PMID: 37248767 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  227. [227]

    Sun Y, Veccia D, Song G et al.. “Acid-Suppressive Therapy Choice and Risk of Treatment Escalation in Inflammatory Bowel Disease: A Real-World Comparative Retrospective Study to Inform Personalized Treatment.” Journal of personalized medicine (2026). PMID: 42042559 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control
  228. [228]

    Feuerstadt P, Harvey A, Yoho DS et al.. “Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37256213 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History
  229. [229]

    Mehta N, Goodenough D, Gupta NK et al.. “Recurrent Clostridioides difficile Infection and Outcome of Fecal Microbiota Transplantation Use: A Population-Based Assessment.” Open forum infectious diseases (2024). PMID: 38975247 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  230. [230]

    Stewart AG, Chen SCA, Hamilton K et al.. “Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia.” Open forum infectious diseases (2023). PMID: 37274181 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  231. [231]

    de la Villa S, Herrero S, Muñoz P et al.. “Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 36776780 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  232. [232]

    Hunt A, Danziger LH, Johnson S et al.. “Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 38665169 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  233. [233]

    Tillotson G, Archbald-Pannone L, Johnson S et al.. “Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities.” Open forum infectious diseases (2022). PMID: 36686631 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Complications
  234. [234]

    Selvarajan T, Kannekanti L, Green A et al.. “Breaking the storm: canakinumab as salvage therapy for refractory macrophage activation syndrome in pediatric systemic lupus erythematosus-a case report.” Pediatric rheumatology online journal (2026). PMID: 42243916 ↗

    L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  235. [235]

    Mudrik-Zohar H, Ong SWX, Tong SYC et al.. “Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42397386 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  236. [236]

    Kitagawa H, Aso S, Hirano Y et al.. “Effect of Broad-Spectrum Antibiotic Prophylaxis on Post-Pancreatoduodenectomy Infectious Complications: Nationwide Inpatient Database Study in Japan.” Annals of gastroenterological surgery (2026). PMID: 42395136 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  237. [237]

    Yousef A, Wang N, Yousef M et al.. “Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth.” Journal of clinical medicine (2026). PMID: 42355617 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  238. [238]

    Berenson CS, Lashner B, Korman LY et al.. “Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37539715 ↗

    L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  239. [239]

    Klompas M, McKenna C, Ochoa A et al.. “Ultra-Short-Course Antibiotics for Suspected Pneumonia With Preserved Oxygenation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35883250 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  240. [240]

    Ilges D, Ritchie DJ, Krekel T et al.. “Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34805436 ↗

    L2COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  241. [241]

    McDonald EG, Butler-Laporte G, Brophy JM et al.. “Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41758514 ↗

    L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  242. [242]

    Bryant JA, Vulić M, Walsh EA et al.. “The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.” Nature medicine (2026). PMID: 41491103 ↗

    L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  243. [243]

    Chu T, Yuan X, Wang T et al.. “The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies.” PeerJ (2026). PMID: 41907457 ↗

    L2SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  244. [244]

    Yee KL, Kleijn HJ, Kerbusch T et al.. “Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.” Antimicrobial agents and chemotherapy (2019). PMID: 30455246 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  245. [245]

    Greenfield A, Marsh K, Siegfried J et al.. “Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.” Open forum infectious diseases (2021). PMID: 34993258 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  246. [246]

    Britt RS, LaSalvia MT, Padival S et al.. “Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.” Open forum infectious diseases (2019). PMID: 32128338 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  247. [247]

    Alkhushaym N, Alabbad R, Alqarni YS et al.. “Assessment of rifaximin and rifampicin resistance across Clostridioides difficile ribotypes: a systematic review and meta-analysis.” Letters in applied microbiology (2026). PMID: 41604218 ↗

    L2SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  248. [248]

    Psarrakis C, Tziolos NR, Matzarakis V et al.. “A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.” Cell reports. Medicine (2026). PMID: 41483804 ↗

    L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  249. [249]

    Kaple CE, Cadnum JL, Redmond SN et al.. “A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool.” Journal of clinical microbiology (2026). PMID: 42283494 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  250. [250]

    Arias-Sánchez A, Casadiego-Payares S, Acosta-Parada C et al.. “Age-related clinical and therapeutic differences during a hospital outbreak of Clostridioides difficile infection in Colombia.” American journal of infection control (2026). PMID: 42217737 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  251. [251]

    Olesen RH, Larsen EB, Rubak T et al.. “Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40243343 ↗

    L2RCTCited in: History and Evolution of Treatment
  252. [252]

    Morgan DJ, Dubberke ER, Hink T et al.. “The Impact of Universal Glove and Gown Use on Clostridioides Difficile Acquisition: A Cluster-Randomized Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35776131 ↗

    L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control
  253. [253]

    Rock C, Hsu YJ, Curless MS et al.. “Ultraviolet-C Light Evaluation as Adjunct Disinfection to Remove Multidrug-Resistant Organisms.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34636853 ↗

    L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  254. [254]

    Cook D, Deane A, Lauzier F et al.. “Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.” The New England journal of medicine (2024). PMID: 38875111 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control
  255. [255]

    Vehreschild MJGT, Ducher A, Louie T et al.. “An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.” The Journal of antimicrobial chemotherapy (2022). PMID: 35016205 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  256. [256]

    Garey KW, Begum K, Lancaster C et al.. “A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.” The Journal of antimicrobial chemotherapy (2020). PMID: 32892222 ↗

    L1RCTCited in: History and Evolution of Treatment
  257. [257]

    Reveles KR, Gonzales-Luna AJ, Golan Y et al.. “Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study.” Open forum infectious diseases (2024). PMID: 39006315 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  258. [258]

    Escudero-Sanchez R, Muriel García A, García Fernández S et al.. “Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.” The Journal of antimicrobial chemotherapy (2022). PMID: 35403189 ↗

    L2COHORTCited in: History and Evolution of Treatment
  259. [259]

    Eriksen LL, Støy S, Mejlby Hansen M et al.. “Dynamics in Circulating Immune Cell Subsets After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.” Clinical and translational gastroenterology (2026). PMID: 41738638 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  260. [260]

    Ayele H, Jo J, Begum K et al.. “A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk.” The Journal of infectious diseases (2025). PMID: 41081530 ↗

    L1RCTCited in: History and Evolution of Treatment
  261. [261]

    Keating JA, McKinley L, Dolan K et al.. “Health care worker experiences with a universal gloving intervention to prevent Clostridioides difficile infection: A qualitative study.” American journal of infection control (2025). PMID: 41046913 ↗

    L5RCTCited in: History and Evolution of Treatment, Prevention and Infection Control
  262. [262]

    Marreddy RKR, Nguyen N, Dureja C et al.. “Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent.” Antimicrobial agents and chemotherapy (2025). PMID: 41405459 ↗

    L5OTHERCited in: History and Evolution of Treatment
  263. [263]

    Deshpande A, Wu X, Huo W et al.. “Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases.” Antimicrobial agents and chemotherapy (2020). PMID: 32457109 ↗

    L5OTHERCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  264. [264]

    Karlowsky JA, Adam HJ, Baxter MR et al.. “Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.” The Journal of antimicrobial chemotherapy (2020). PMID: 32294172 ↗

    L4OTHERCited in: History and Evolution of Treatment
  265. [265]

    Collins CD, Bookal RS, Malani AN et al.. “Antibiotic Use in Patients With β-Lactam Allergies and Pneumonia: Impact of an Antibiotic Side Chain-Based Cross-Reactivity Chart Combined With Enhanced Allergy Assessment.” Open forum infectious diseases (2021). PMID: 34988249 ↗

    L2OTHERCited in: History and Evolution of Treatment
  266. [266]

    Straub TJ, Lombardo MJ, Bryant JA et al.. “Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37823484 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship
  267. [267]

    Aslan AT, Tanriverdi LH, Hernandez AV et al.. “Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Open forum infectious diseases (2025). PMID: 41018707 ↗

    L1SR_MA_RCTCited in: Antimicrobial Resistance and Stewardship, Complications
  268. [268]

    Baker MA, Sands KE, Huang SS et al.. “The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34370014 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  269. [269]

    Ray MJ, Strnad LC, Tucker KJ et al.. “Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38743579 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  270. [270]

    Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗

    L1TRIAL_NONRANDOMCited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  271. [271]

    Esberard M, Hallier M, Liu W et al.. “6S RNA-Dependent Susceptibility to RNA Polymerase Inhibitors.” Antimicrobial agents and chemotherapy (2022). PMID: 35389235 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  272. [272]

    Sandhu BK, Edwards AN, Anderson SE et al.. “Regulation and Anaerobic Function of the Clostridioides difficile β-Lactamase.” Antimicrobial agents and chemotherapy (2019). PMID: 31611350 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  273. [273]

    Kolte B, Nübel U. “Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.” The Journal of antimicrobial chemotherapy (2024). PMID: 38598696 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  274. [274]

    Raybardhan S, Langford B, Forrest R et al.. “Institutional spillover effects of antimicrobial use on antimicrobial resistance and Clostridioides difficile: a systematic review.” Antimicrobial stewardship & healthcare epidemiology : ASHE (2026). PMID: 42064230 ↗

    L2SR_OBSCited in: Antimicrobial Resistance and Stewardship
  275. [275]

    Boyanova L, Boyanova LY, Medeiros J et al.. “Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353704 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  276. [276]

    Ryazanov V, Vershinina I, Inchagova K et al.. “Fecal microbiota and microbial community transplantation: a review of current research.” Frontiers in microbiology (2026). PMID: 42326403 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  277. [277]

    Samuelsen Ø, López-Causapé C, Aarestrup FM et al.. “The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the European Committee on Antimicrobial Susceptibility Testing Subcommittee.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42142806 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  278. [278]

    Abdessamad H, Abdallah D, Attieh R et al.. “Revisiting fluoroquinolone prophylaxis in haematological malignancies and hematopoietic cell transplantation: A decade of evidence and gaps in understanding the impact of gut colonization with fluoroquinolone-resistant Enterobacterales.” International journal of antimicrobial agents (2026). PMID: 42055352 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  279. [279]

    Eubank TA, Dureja C, Gonzales-Luna AJ et al.. “Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Specific Ribotypes.” Open forum infectious diseases (2024). PMID: 39512425 ↗

    L3OTHERCited in: Antimicrobial Resistance and Stewardship
  280. [280]

    Endres BT, Begum K, Sun H et al.. “Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains.” Open forum infectious diseases (2019). PMID: 30793006 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  281. [281]

    Eudy JL, Pallotta AM, Neuner EA et al.. “Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort.” Open forum infectious diseases (2020). PMID: 33269298 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  282. [282]

    Hourigan SK, Ahn M, Gibson KM et al.. “Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden.” Open forum infectious diseases (2019). PMID: 31660343 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  283. [283]

    Tsalik EL, Prasad NK, Fleisher LA. “Advancing Antimicrobial Stewardship With Diagnostic Excellence: The Role of Bayesian Reasoning.” Open forum infectious diseases (2026). PMID: 42052289 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  284. [284]

    Gonzales-Luna AJ, Carlson TJ, Garey KW. “Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051970 ↗

    L5REVIEW_NARRATIVECited in: Complications
  285. [285]

    Bej TA, Wilson BM, Akpoji UC et al.. “Feasibility of a Low-Intensity Intervention to Influence Antibiotic Prescribing Rates Use in Outpatient Settings: A Cluster Randomized Controlled Clinical Trial.” Open forum infectious diseases (2024). PMID: 39758744 ↗

    L1TRIAL_NONRANDOMCited in: Complications
  286. [286]

    Baral B, Parajuli M, Pinilla J et al.. “Safety and efficacy of oral microbiome therapy for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.” Scandinavian journal of gastroenterology (2026). PMID: 41543263 ↗

    L1SR_MA_RCTCited in: Complications
  287. [287]

    Omar MA, Katrib M, Shekhar R et al.. “Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.” Journal of clinical medicine (2026). PMID: 41976918 ↗

    L1SR_OBSCited in: Complications, Prevention and Infection Control
  288. [288]

    Nashtar MA, Garipoglu G, Traut I et al.. “From ward to intensive care unit: clinical drivers of adverse outcomes in Clostridioides difficile infection - A retrospective cohort study.” The Journal of hospital infection (2026). PMID: 41653983 ↗

    L3COHORTCited in: Complications
  289. [289]

    Greco Kinney A, Kovacic Scherrer N, Sarkar S et al.. “β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.” The Journal of antimicrobial chemotherapy (2023). PMID: 37814829 ↗

    L2OTHERCited in: Complications
  290. [290]

    Renoncourt T, Dossoubadjiokila J, Mondet L et al.. “Evaluation of the tolerance of ceftriaxone by subcutaneous route in patients ≥75 years old in geriatric departments: a prospective observational study.” The Journal of antimicrobial chemotherapy (2023). PMID: 37051882 ↗

    L4OTHERCited in: Complications
  291. [291]

    Tucker EC, Angelica B, Mathias RM et al.. “Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia.” Open forum infectious diseases (2025). PMID: 40160347 ↗

    L4OTHERCited in: Complications
  292. [292]

    Madden GR, Enfield KB, Sifri CD. “Patient Outcomes With Prevented vs Negative Clostridioides difficile Tests Using a Computerized Clinical Decision Support Tool.” Open forum infectious diseases (2020). PMID: 32328506 ↗

    L3OTHERCited in: Complications
  293. [293]

    Turner NA, Warren BG, Gergen-Teague MF et al.. “Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34017999 ↗

    L1RCTCited in: Prognosis and Natural History
  294. [294]

    Sahrmann JM, Olsen MA, Stwalley D et al.. “Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36285546 ↗

    L3OTHERCited in: Prognosis and Natural History
  295. [295]

    Yu H, Alfred T, Nguyen JL et al.. “Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35686435 ↗

    L3OTHERCited in: Prognosis and Natural History
  296. [296]

    Pruna ED, Davidescu L, Sorop-Florea M et al.. “Multimodal Hand Hygiene Interventions and Clinical Healthcare-Associated Infection Outcomes in Acute Care Hospitals: A Systematic Review of Quasi-Experimental Studies.” Journal of clinical medicine (2026). PMID: 42194842 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  297. [297]

    Chen W, Pan X, Ji J et al.. “Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis.” Frontiers in nutrition (2026). PMID: 41878577 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  298. [298]

    De Wolfe TJ, Kates AE, Barko L et al.. “Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies.” Antimicrobial agents and chemotherapy (2019). PMID: 30988143 ↗

    L5OTHERCited in: Prognosis and Natural History
  299. [299]

    Shen WJ, Deshpande A, Hevener KE et al.. “Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates.” The Journal of antimicrobial chemotherapy (2020). PMID: 31873741 ↗

    L5OTHERCited in: Prognosis and Natural History
  300. [300]

    West RM, Smith CJ, Pavitt SH et al.. “'Warning: allergic to penicillin': association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes.” The Journal of antimicrobial chemotherapy (2019). PMID: 31225607 ↗

    L3OTHERCited in: Prognosis and Natural History
  301. [301]

    Pereira JA, McGeer A, Tomovici A et al.. “The Clinical Burden of Clostridioides difficile in Ontario, Canada.” Open forum infectious diseases (2019). PMID: 32025524 ↗

    L2OTHERCited in: Prognosis and Natural History
  302. [302]

    Dorazio J, Chiappelli AL, Shields RK et al.. “Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection.” Open forum infectious diseases (2023). PMID: 37351452 ↗

    L2OTHERCited in: Prognosis and Natural History
  303. [303]

    Alsoubani M, Chow JK, Rodday AM et al.. “Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study.” Open forum infectious diseases (2023). PMID: 38204563 ↗

    L2OTHERCited in: Prognosis and Natural History
  304. [304]

    Johnson SW, Brown SV, Priest DH. “Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31560051 ↗

    L1RCTCited in: Prevention and Infection Control
  305. [305]

    Poirier D, Gervais P, Fuchs M et al.. “Predictors of Clostridioides difficile Infection Among Asymptomatic, Colonized Patients: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31290544 ↗

    L2COHORTCited in: Prevention and Infection Control
  306. [306]

    Heil EL, Harris AD, Brown C et al.. “A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33972996 ↗

    L2OTHERCited in: Prevention and Infection Control
  307. [307]

    Butler AM, Nickel KB, Olsen MA et al.. “Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 39442057 ↗

    L2OTHERCited in: Prevention and Infection Control
  308. [308]

    Pakyz AL, Orndahl CM, Johns A et al.. “Impact of the Centers for Medicare and Medicaid Services Sepsis Core Measure on Antibiotic Use.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32827032 ↗

    L2OTHERCited in: Prevention and Infection Control
  309. [309]

    Wombwell E, Patterson ME, Bransteitter B et al.. “The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32575126 ↗

    L2OTHERCited in: Prevention and Infection Control
  310. [310]

    Jones KM, Greene MT, Meddings J et al.. “Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40298392 ↗

    L2OTHERCited in: Prevention and Infection Control
  311. [311]

    Brothers AW, Pak DJ, Poole NM et al.. “Individualized Antibiotic Plans as a Quality Improvement Initiative to Reduce Carbapenem Use for Hematopoietic Cell Transplant Patients at a Freestanding Pediatric Hospital.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37647637 ↗

    L4OTHERCited in: Prevention and Infection Control, Special Hosts and Populations
  312. [312]

    DeJohn I, Liu C, Brammer C et al.. “Secondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study.” Open forum infectious diseases (2026). PMID: 42403911 ↗

    L2COHORTCited in: Prevention and Infection Control
  313. [313]

    Keating JA, Xu T, Graham MB et al.. “Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2025). PMID: 40601321 ↗

    L1RCTCited in: Prevention and Infection Control
  314. [314]

    Tetteh EK, Obeng H, Atkinson A et al.. “Dissemination of a facilitation strategy to de-implement unnecessary post-operative antibiotics at children's hospitals: The Optimizing Perioperative Antibiotic in Children (OPerAtiC) trial 2.0.” Implementation science : IS (2025). PMID: 41214788 ↗

    L5TRIAL_NONRANDOMCited in: Prevention and Infection Control, Special Hosts and Populations
  315. [315]

    Hirsch W, Fischer M, Khoruts A et al.. “Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study.” Open forum infectious diseases (2025). PMID: 40103733 ↗

    L2OTHERCited in: Prevention and Infection Control
  316. [316]

    Prosty C, Bortolussi-Courval É, Lee J et al.. “Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians.” Open forum infectious diseases (2025). PMID: 40395460 ↗

    L5OTHERCited in: Prevention and Infection Control
  317. [317]

    Wolf J, Kalocsai K, Fortuny C et al.. “Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773143 ↗

    L1RCTCited in: Special Hosts and Populations
  318. [318]

    Barbar R, Brazelton JN, Carroll KC et al.. “Molecular Epidemiology and Genetic Relatedness of Clostridioides difficile Isolates in Pediatric Oncology and Transplant Patients Using Whole Genome Sequencing.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35675378 ↗

    L2OTHERCited in: Special Hosts and Populations
  319. [319]

    Cherny KE, Muscat EB, Balaji A et al.. “Association Between Clostridium innocuum and Antibiotic-Associated Diarrhea in Adults and Children: A Cross-sectional Study and Comparative Genomics Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35724319 ↗

    L4OTHERCited in: Special Hosts and Populations
  320. [320]

    Nussbaum EZ, Koo S, Kotton CN. “Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38195100 ↗

    L2OTHERCited in: Special Hosts and Populations
  321. [321]

    Lee JD, Heintz BH, Mosher HJ et al.. “Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33382398 ↗

    L2OTHERCited in: Special Hosts and Populations
  322. [322]

    Rogers WS, Westblade LF, Soave R et al.. “Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31687767 ↗

    L4OTHERCited in: Special Hosts and Populations
  323. [323]

    Coritsidis GN, Yaphe S, Rahkman I et al.. “Outpatient Antibiotic Prescribing Patterns for Adult End-Stage Renal Disease Patients in New York State.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33277995 ↗

    L3OTHERCited in: Special Hosts and Populations
  324. [324]

    O'Leary EN, Edwards JR, Srinivasan A et al.. “National Healthcare Safety Network Standardized Antimicrobial Administration Ratios (SAARs): A Progress Report and Risk Modeling Update Using 2017 Data.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32215655 ↗

    L4OTHERCited in: Special Hosts and Populations
  325. [325]

    Longhitano A, Roder C, Blackmore T et al.. “Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand.” Internal medicine journal (2025). PMID: 40035163 ↗

    L1GUIDELINECited in: Special Hosts and Populations
  326. [326]

    Berry P, Tariq R, Pardi DS et al.. “Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40759389 ↗

    L4SR_OBSCited in: Special Hosts and Populations
  327. [327]

    Dell'Acqua R, Parrinello MH, Clerici D et al.. “Antibacterial prophylaxis and antimicrobial stewardship in the era of innovative therapies for haematological malignancies: transplantation, cellular therapies and new drugs.” JAC-antimicrobial resistance (2026). PMID: 41959696 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  328. [328]

    Wang R, Li X, Zhang T. “Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41723281 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  329. [329]

    Kinsella P, Thursky K, Slavin MA et al.. “From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts.” Expert review of anti-infective therapy (2025). PMID: 40785091 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  330. [330]

    Kociolek LK, Sandora TJ, Mehrotra P. “Clostridioides difficile in Children.” Infectious disease clinics of North America (2025). PMID: 40781053 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations

Revision History

All updates applied to this page

Loading revisions…